Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 2Neuroblastoma 2Melanoma 2Lung Neoplasms 2Gliosarcoma 2Glioblastoma 2Unilateral Breast Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Ganglioneuroblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

sargramostim 1ribociclib 1palbociclib 1abemaciclib 1Letrozole 1Cyclophosphamide 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Unilateral Breast Neoplasms × sargramostim × Clear all
NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Academic and Community Cancer Research United

Phase 2 Active not recruiting
280 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡